Key messages Stephen S Lim, et al. Lancet 2007; 370: 2054-62

Key messages

Stephen S Lim, et al. Lancet 2007; 370: 2054-62

Countries that account for 80% of global chronic disease deaths in low-income and middle-income countries


Main model parameters


Example of an absolute risk chart

using age, sex, smoking status, systolic blood pressure, and

body-mass index

*Numbers are 10-year risk of fatal ischaemic heart disease or

cardiovascular events in Mexico


Patterns of scale-up of a multidrug regimen for patients at high risk of cardiovascular disease by Commission on

Macroeconomics in Health (CMH) category, expressed as a proportion of those accessing health services


Effects of diff erent individual drugs, measured as relative risk, on fatal and non-fatal ischaemic

heart disease and cerebrovascular disease


Patient cost parameters


Cumulative thousands of deaths averted with a multidrug regimen for the prevention of

cardiovascular disease by sex, 2006-15


Person-years of treatment and number of deaths averted by age and sex, 2006-15


Cumulative financial cost of scaling up a multidrug regimen for the prevention

of cardiovascular disease, 2006-15


Average yearly cost (US$ per head) of scaling up a multidrug regimen for the prevention ofcardiovascular disease by country, 2006-15


Average yearly cost (proportion of current health expenditure) of scaling up a multidrug regimen for the

prevention of cardiovascular disease by country, 2006-15


Documents

Key messages Stephen S Lim, et al. Lancet 2007; 370: 2054-62